Wilmington, DE and Ashdod, Israel, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (OTCQB: IGAP),
innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with type 2 diabetes
and pre-diabetes, announced today that it has received its first order from CuraTec Nordic http://www.curatec.dk its exclusive distributor for the Nordic Countries.
Kim Frederiksen, the CEO of CuraTec Nordic, commented “We are excited about the opportunity of bringing
GlucoTrack® to the marketplace, and we have an aggressive plan to launch this revolutionary product. Diabetics will finally have a
way of effectively managing their disease in a pain free manner.”
This initial order of 100 units of GlucoTrack® will be delivered by the middle of September and will be used to
initiate discussions with key stakeholders, including local diabetes centers, key physicians and payers, as commercialization
begins in Denmark, Sweden, Norway, and Finland. Additional orders are expected before year end.
“We are encouraged by the quick progress being made with Curatec Nordic” said David Podwalski, Integrity’s Chief
Commercial Officer. “We strongly believe that our partnership with CuraTec Nordic will allow many diabetics and pre-diabetics in
the Scandinavian markets to take advantage of the many benefits of GlucoTrack®.”
The commercialization of GlucoTrack® in Europe is one of Integrity’s near-term priorities. The Company has
previously signed a distribution agreement for the Netherlands, and through its distributor is in discussions with local insurance
companies for reimbursement of GlucoTrack®.
About GlucoTrack®
GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a
minute without finger pricking or any pain. GlucoTrack® features a small sensor that clips to the earlobe and measures the user’s
glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm
and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results
are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values
graphically, enabling the user to monitor glucose levels over time.
GlucoTrack® has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea for type 2
diabetes and pre-diabetics, and is currently in the early stages of commercialization in Europe, South Korea, and other
geographies. GlucoTrack® is expected to begin clinical trials for United States FDA approval. The product is currently experimental
in the United States and is limited to investigational use only.
About Integrity Applications, Inc.
Integrity Applications, Inc. (OTCQB: IGAP) was founded in 2001 and is focused on the design, development, and commercialization of
non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed
GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute
without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications
Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information,
please visit http://www.integrity-app.com/ and http://www.glucotrack.com.
Investor Contact
Sami Sassoun, CFO Integrity Applications
SamiS@integrity-app.com
+972 (8) 675-7878 Ext. 400
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify
forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results
and could cause such results to differ materially from any forward-looking statements that may be made in this news release.
Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to
raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks
relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution
agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and
the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (the
“SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 31,
2017.
